The need for a blueprint emergency plan to avoid a HPAPI crisis

SMi Group21 - 22 October 2019, Boston, USA.
With a massive growth within the HPAPI market, manufacturers cannot afford to be complacent in terms of staff training, utilization of approved technology and blueprint accident plans. Straying away from the correct procedures can have a massive affect on your business and industry.

At the inaugural HPAPI USA conference, these issues will be discussed and give delegates the opportunity to hear from industry experts who will share their experiences and arm attendees with the safety strategies to implement into their organization.

Ayasha Ovals from Taro Pharmaceuticals will provide a keynote address on Day One of the conference, where she will give insights into emergency procedures for HPAPI disasters and how to manage an accident, including long term cost savings, managing risk, fail-safe procedure and forward planning.

Industrial hygiene and potent compound containment will be discussed by Joseph Grill, former Associate Director from Purdue Pharma, where he will share insights on common pitfalls in industrial hygiene, flexible containment and the potential of hastening R&D.

Sakari Consultants, President & Principle, Patricia Weidemanwill focus on training and managing workers with HPAPI exposure, along with the best available techniques for cleaning and waste management. She will also look at technological innovations for containment and transfer technologies, ensuring staff are sufficiently trained and ensure they understand the equipment they are utilising.

The programme with full speaker line-up is available to download at www.hpapi-usa.com

Plus, two HPAPI USA Post Conference Workshops will take place in Boston on October 23rd:

Workshop A: The roadmap from assessing HPAPI hazards to containment implementation along with CDMO dynamics hosted byDr Janet Gould, Principal Toxicologist, SafeBridge Consultants and Charlyn Reihamn, Principle Occupational Health Consultant,SafeBridge Consultants

Workshop B: How to sell your containment project to management: financial justification for containment solutions hosted by DrDavid Eherts, Vice President Global EHS, Allergan Inc

For those interested, an early bird saving of $300 is available for conference tickets booked before Friday 28th June. Register online at www.hpapi-usa.com

Sponsoredby BSP Pharmaceuticals, LONZA, Minakem, SafeBridge Consultants

For delegate enquiries, please contact Fateja Begum on +44 (0)20 7827 6184 or This email address is being protected from spambots. You need JavaScript enabled to view it.

For sponsorship, exhibition and branding enquiries, please contact Alia Malick on +44 (0)20 7827 6168 or This email address is being protected from spambots. You need JavaScript enabled to view it.

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 This email address is being protected from spambots. You need JavaScript enabled to view it.

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

AstraZeneca amends collaboration with Ironwood for…

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclo...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

FDA grants Fast Track designation for Farxiga in h…

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk ...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Gene-targeted cancer drugs, slow release overcome …

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, prot...

Educational campaign helps teens and their caregiv…

Teenagers face many challenges, and growing up with a chronic skin disease called atopic dermatitis (AD) can impact the ups and downs and transitions to young adulthood. ...

Study points to new drug target in fight against c…

Researchers have identified a potential new drug target in the fight against cancer. In a study this week in the Proceedings of the National Academy of Sciences, an inter...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Dengue virus becoming resistant to vaccines and th…

Researchers from Duke-NUS Medical School (DukeNUS), in collaboration with the Agency for Science, Technology and Research (A*STAR)'s Bioinformatics Institute (BII), and t...